Matthew Witmer, MD
Retina Specialist · Rochester, NYNPI 1235321167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,350 of the $61,626 with a category attached, or 81.7%. Astellas Pharma US Inc accounts for 69.3% of it on its own, with 12 other manufacturers making up the rest. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $493.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$43K
- AbbVie$17K
- Regeneron Healthcare Solutions, Inc.$449
- Genentech USA, Inc.$252
- Alimera Sciences, Inc.$202
- Alcon$140
- plus $433 from 7 others
Across 8 payments — averaging $23,053 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$163K
- AbbVie$22K
What the payments were for
- Consulting fees$2,7004%
- Speaking & faculty fees$50,35082%
- Travel & lodging$4,7138%
- Food & beverage$3,8626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 42 | $42,696 |
| AbbVie(2 entities) | 32 | $17,454 |
| Regeneron Healthcare Solutions, Inc. | 14 | $449 |
| Genentech USA, Inc. | 11 | $252 |
| Alimera Sciences, Inc. | 10 | $202 |
| Alcon | 1 | $140 |
| ANI Pharmaceuticals, Inc. | 1 | $119 |
| Coherus Oncology, Inc. | 3 | $84 |
| Eyepoint US, Inc. | 4 | $84 |
| Novartis | 4 | $70 |
| Harrow Eye, LLC | 1 | $32 |
| Sandoz | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$28,796
- OZURDEX$8,024
- Centurion$140
- EYLEA$123
- PURIFIED CORTROPHIN GEL$119
How this compares
$61,626 in reported general payments places this provider in the 90th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 154 | $9,422 |
| Brimonidine Tartrate | 41 | $2,715 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 98 | $1,591 |
| ValacyclovirValacyclovir Hcl | 22 | $824 |
| Acetazolamide | 11 | $685 |
| Timolol Maleate | 72 | $606 |
| Tobramycin | 122 | $544 |
| Latanoprost | 91 | $501 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Edward HallRochester$38K
- Brian ConnollyRochester$7K
- Steven RoseRochester$5K
- Vikas KhetanRochester$3K
- Sana IdreesRochester$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.